ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 1820

Disruption of Ca2+ Homeostasis and Enhanced Ca2+ Signaling in Scleroderma Fibroblasts Is Due to the Vicious Cycle Formed by Mitochondrial-derived Reactive Oxygen Species, CaMKII, and ER Extrusion Pump RYR2

Systemic Sclerosis & Related Disorders – Basic Science Poster II

10:30AM-12:30PM: Abstract Number: 2136

Distal Radius Correlation with Femur and Lumbar Spine T-scores: A Comprehensive Analysis

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

10:30AM-12:30PM: Abstract Number: L06

Distinct Cytokine and Cytokine Receptor Expression Patterns Characterize Different Subtypes of Inflammatory Myopathies

(L01–L14) Late-Breaking Posters

10:30AM-12:30PM: Abstract Number: 1856

Distinct Proliferative and Special Properties of Peripheral Helper T Cells in RA Synovium

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 1818

Distribution and Morphological Changes of Adventitial Fibroblasts in Healthy and Scleroderma Skin

Systemic Sclerosis & Related Disorders – Basic Science Poster II

10:30AM-12:30PM: Abstract Number: 1773

Divergent Genetic Architecture in Boys and Girls with NEMO-deleted Exon 5 Autoinflammatory Syndrome (NEMO-NDAS) Implies Role for Wildtype Effector Cells

Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2328

Do Patients That Develop PsA Before Psoriasis Have Different Disease Outcomes?

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2350

Do Smoking and Obesity Impact Secukinumab Treatment Outcomes? Real-world Data from 1,202 European Patients with Psoriatic Arthritis

SpA Including PsA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1782

DOCK2 Mutations and Hyper-Inflammatory Syndromes

Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2318

Does the Time Interval Between the Onset of Psoriasis and Psoriatic Arthritis Impact Disease Presentation and Outcomes?

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2431

DORIS Remission in Patients with SLE Treated with Anifrolumab: Post Hoc Analysis from TULIP-1 and TULIP-2 Trials in Patents with No Reported History of Prior Immunosuppressant Use

SLE – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2347

Drug Survival in Spondyloarthritis: Anti-IL17 Outperforms Anti-TNF in First Biologic Treatment

SpA Including PsA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2046

Duration of Disease and Long-term Outcomes in Patients with Difficult-to-treat Recurrent Pericarditis: A Chronic Condition Treated with NSAIDs, Colchicine, Corticosteroids, and Anti-IL-1 Agents

Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2138

DXA-derived 3D Parameters of the Hip Discriminate Prevalent Fragility Fractures in Individuals with Axial Spondyloarthritis

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

10:30AM-12:30PM: Abstract Number: 1892

Early Tumor Necrosis Factor Inhibitor Initiation and Chronic Opioid Use in Individuals with Axial Spondyloarthritis

Epidemiology & Public Health Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].